Lund, Thomas by unknown
Syddansk Universitet
Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic
disease
Fu, Jing; Li, Shirong; Feng, Rentian; Ma, Huihui; Sabeh, Farideh; Roodman, G David; Wang,
Ji; Robinson, Samuel; Guo, X Edward; Lund, Thomas; Normolle, Daniel; Mapara, Markus Y;
Weiss, Stephen J; Lentzsch, Suzanne
Published in:
Journal of Clinical Investigation
DOI:
10.1172/JCI80276
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Citation for pulished version (APA):
Fu, J., Li, S., Feng, R., Ma, H., Sabeh, F., Roodman, G. D., ... Lentzsch, S. (2016). Multiple myeloma-derived
MMP-13 mediates osteoclast fusogenesis and osteolytic disease. Journal of Clinical Investigation, 126(5), 1759-
1772. DOI: 10.1172/JCI80276
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 15. okt.. 2017
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
1 7 5 9jci.org   Volume 126   Number 5   May 2016
Introduction
Multiple myeloma (MM) arises as a consequence of the clonal 
expansion of malignant plasma cells within the BM compartment, 
an event associated with bone destruction and significant comor-
bidities including severe pain, pathologic fractures, and spinal 
cord compression (1). MM cells are commonly found in association 
with sites of active bone resorption, where they secrete a variety of 
pro-osteoclastogenic agents (1, 2). Current agents such as biphos-
phonates for the treatment of MM bone disease are aimed at spe-
cifically targeting osteoclast (OCL) function (3). However, these 
therapeutics only partially inhibit the progression of osteolytic 
lesions (3). Consequently, new treatment strategies that modulate 
MM-OCL interactions are needed to improve patient outcomes. 
While recent studies have identified several MM-derived factors 
that contribute to OCL activation, including receptor activator of 
NF-κB ligand (RANKL) (4), macrophage inflammatory protein 1α 
(MIP-1α) (5), and IL-3 (6), preliminary efforts aimed at targeting 
these molecules have not ameliorated MM-associated bone dis-
ease to a significant degree (7), suggesting that other key, but here-
tofore unknown, factors are operative at the MM-OCL interface.
While screening for osteoclastogenic factors secreted by MM 
cells, we unexpectedly found that the matrix metalloproteinase 
MMP-13 (alternatively termed collagenase-3) is highly expressed 
by human MM cells. MMP-13 is a member of a family of zinc- and 
calcium-dependent proteolytic enzymes that degrade extracel-
lular matrix components during normal physiological processes 
(e.g., embryonic development, reproduction, tissue remodeling, 
and angiogenesis) as well as in pathological conditions such as 
osteoarthritis, tumor invasion, and metastasis (8, 9). In each of 
these scenarios, the key functional activities of MMP-13 have 
been linked directly to its ability to degrade interstitial collagen, a 
critical structural component of all connective tissues, including 
bone, as well as other matrix-associated targets (10–19). How-
ever, in contrast to studies highlighting the degradative activ-
ities of the metalloproteinase, we now report that MM- derived 
MMP-13 serves as a potent secretagogue of OCL fusion and 
bone-resorptive activity independently of its proteolytic activ-
ity by triggering the ERK1/2-dependent regulation of nuclear 
factor of activated T cells, cytoplasmic, calcineurin-depen-
dent 1 (NFATc1) and dendrocyte-expressed 7 transmembrane 
(DC-STAMP) expression. These findings, coupled with data sup-
porting enhanced MMP-13 expression in patients with MM, pro-
vide the first proof to our knowledge of a nonproteolytic role for 
MMP-13 in the development of lytic bone lesions in patients with 
MM, thereby providing a rationale for targeting an unexpected 
effector that is operative within the MM-OCL interface.
Results
MMP-13 expression and regulation in MM cells. While screening 
human MM cell lines for their ability to express MMPs, RPMI 8266 
cells were noted to secrete MMP-13 at levels that far exceeded those 
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In vivo, BM stromal cells (BMSCs) are known to support 
MM cell growth and survival via both contact-dependent and 
-independent mechanisms (20, 21). Hence, we next determined 
whether BMSCs contribute to MMP-13 upregulation in MM cells. 
For this purpose, GFP+ RPMI 8266 cells were cocultured with 
BMSCs in direct contact or, alternatively, in Transwell dishes, 
thereby precluding direct cell-cell contact. Under both coculture 
conditions, MMP-13 was significantly upregulated relative to that 
detected in supernatants from MM or BMSC cultures alone (Fig-
ure 1B), demonstrating that direct cell contact is not required for 
MMP-13 upregulation. Further, MM cells are the major source of 
MMP-13 production in the coculture system, as the MMP13 mRNA 
of other MMPs (e.g., MMP-1, -2, -3, -7, -8, and -12). Though MMP-
1, -2, -3, -7, and -8 levels all fell within detectable ranges, MMP-13 
expression was approximately 300- to 400-fold higher than that 
of all other MMPs assessed (Figure 1A). Further, increased MMP-
13 expression was not confined to RPMI 8266 cells and could be 
detected similarly in all tested human MM cell lines, as determined 
by either MMP-13 fluorimetric assay (Supplemental Figure 1A; sup-
plemental material available online with this article; doi:10.1172/
JCI80276DS1) or collagen zymography (Supplemental Figure 1B). 
Of note, when assessed by zymography, only trace amounts of the 
active form, as opposed to the pro-form, of MMP-13 were detected 
(Supplemental Figure 1B).
Figure 1. Cell-autonomous and BMSC-dependent regulation of MMP-13 in MM cells. (A) MMP protein expression levels in human RPMI 8266 MM cells 
as determined by Luminex assay (mean ± SD; n = 3). (B) BMSCs were isolated from patients with MM and cultured with RPMI 8226 cells in direct contact 
(Contact) or in Transwell dishes (TW). MMP-13 concentrations in cell-free supernatants were determined by immunoassay (mean ± SD; n = 3). Data are 
representative of 2 independent experiments. **P ≤ 0.01, by ANOVA. (C) GFP+ RPMI 8226 cells were cocultured with BMSCs in direct contact or in Transwell 
dishes. MMP13 mRNA expression in RPMI 8226 cells was determined by qRT-PCR after separating GFP– BMSCs and GFP+ RPMI 8266 cells by flow cytome-
try. Data represent the mean ± SD (n = 3) and are representative of 2 independent experiments. **P ≤ 0.01, by ANOVA. (D) MM cell lines were cultured with 
or without CM prepared from BMSCs and a neutralizing Ab directed against IL-6 (5 μg/ml) for 24 hours. MMP13 mRNA levels were determined by qRT-PCR. 
Data represent the mean ± SD (n = 3) and are representative of 3 independent experiments. **P ≤ 0.01, by ANOVA. (E) MM cells were treated with IL-6 (20 
ng/ml) for 24 hours, and MMP13 mRNA levels were determined by qRT-PCR. Data represent the mean ± SD (n = 3) and are representative of 3 independent 
experiments. **P ≤ 0.01, by 2-tailed Student’s t test. (F) RPMI 8266 cells were treated with IL-6 (20 ng/ml) for the indicated durations, and MMP-13 protein 
levels were analyzed in culture supernatants (SN) by Western blotting. Data are representative of 2 independent experiments.
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adding a neutralizing Ab against IL-6 to the cultures (Figure 1D), 
suggesting that IL-6 is the key cytokine that induces MMP-13 in 
BMSC CM. In accordance with this finding, direct treatment of 
MM cells with exogenous IL-6 upregulated MMP13 transcription 
and protein expression (Figure 1, E and F).
level in purified GFP+ RPMI 8266 cells was more than 100-fold 
higher than that detected in BMSCs (Figure 1C). Similar results 
were obtained when any of the panel of human MM cell lines were 
incubated with BMSC-conditioned medium (CM). Further, the 
upregulation of MMP-13 could be almost completely blocked by 
Figure 2. MMP-13 mediates MM-induced OCL fusion and bone resorption. (A) Mouse nonadherent BM cells were cocultured with 5TGM1-EV or 5TGM1–
MMP-13–KD #1 cells in Transwell dishes with M-CSF (10 ng/ml) and RANKL (50 ng/ml) for 4 days, with pro–MMP-13 added as indicated. OCLs were stained 
for TRAP and images captured as described in Methods. Scale bars: 100 μm. Data are representative of 3 independent experiments. CT, control. (B) Mouse 
OCL size (left panel), number of nuclei per OCL (middle panel), and number of OCLs per field (right panel) were assessed by microscopy and ImageJ soft-
ware (NIH). Data represent the mean ± SEM (n = 3). *P ≤ 0.05 and **P ≤ 0.01, by ANOVA. (C) Mouse nonadherent BM cells were cultured with the indicated 
concentrations of pro–MMP-13 or vehicle during OCL formation in the presence of M-CSF (10 ng/ml) and RANKL (50 ng/ml). TRAP+ OCLs were scored 
microscopically. Scale bars: 100 μm. Data are representative of 4 independent experiments. (D) Mouse OCL size (left panel), number of nuclei per OCL 
(middle panel), and number of OCLs per field (right panel) were determined as above. Data represent the mean ± SEM (n = 3). P ≤ 0.0001, by linear regres-
sion (left panel) and Poisson regression (middle panel); P > 0.05 by Poisson regression (right panel). (E) Human mononuclear BM cells were cultured with 
the indicated concentrations of MMP-13 or vehicle during OCL formation in the presence of M-CSF (10 ng/ml) and RANKL (50 ng/ml). OCL numbers were 
determined by CD51/CD61 staining with 23c6 Ab and scored microscopically. Scale bars: 100 μm. Data are representative of 3 independent experiments. (F) 
Human OCL size, number of nuclei per OCL, and number of OCLs per well (right panel) were determined as above. Data represent the mean ± SEM (n = 3).  
P  ≤ 0.0001, by linear regression (left panel) and Poisson regression (middle panel); P > 0.05 by Poisson regression (right panel).
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tion were reversed by supplementing the cultures with exogenous 
pro–MMP-13 (Supplemental Figure 6, B and C), without affecting 
pre-OCL proliferation rates (Supplemental Figure 6F). Taken 
together, these data indicate that MMP-13 modulates OCL fusion 
and bone-resorptive activity in both a cell-autonomous and a non–
cell-autonomous manner.
MMP-13 induces OCL formation independently of its proteolytic 
activity by an ERK1/2–DC-STAMP–dependent process. MMP-in-
duced activities are most frequently associated with the conversion 
of the proenzyme to a mature form that is able to hydrolyze target 
substrates (8, 9). Hence, as the MMP-13 zymogen enhanced OCL 
fusion and function in our in vitro cultures, we sought to determine 
(a) whether pro–MMP-13 is processed into its catalytically active 
form by BM-derived mononuclear cells and (b) whether proteolytic 
activity is required for the induction of OCL formation. Unexpect-
edly, the conversion of the MMP-13 zymogen to its active form was 
not detected in BM mononuclear cell cultures in the CM (Figure 
3A, upper panel) or in association with the OCL surface (Figure 
3A, lower panel), suggesting that MMP-13 enzymatic activity is not 
necessarily required for the stimulation of osteoclastogenic activ-
ity. Indeed, neither of the 2 specific and potent MMP-13 enzymatic 
inhibitors CP544439 (IC50 = 0.7 nM) (23) or CAS 544678-85-5 
(IC50 = 8 nM) (24) affected MMP-13–induced OCL formation (Fig-
ure 3, B and C) at concentrations that completely blocked MMP-13 
enzymatic activity (Supplemental Figure 7A).
To confirm that the proteolytic activity of MMP-13 is not 
required for induction of OCL fusion and activity, an enzymati-
cally inactive mutant of MMP-13 was generated by introducing 
an E223A mutation within the zinc-binding motif of the protein-
ase (Figure 4A and ref. 25). As expected, the MMP-13 WT protein 
rapidly underwent autoactivation in the presence of p-aminophe-
nylmercuric acetate (a process dependent on an intact catalytic 
domain), while the MMP-13 E223A mutant remained locked in its 
proform state, as confirmed by a fluorometric assay that showed an 
absence of MMP-13 enzymatic activity (Figure 4B) or by collagen 
zymography (Supplemental Figure 7B). Nevertheless, both MMP-
13 WT and MMP-13 E223A showed similar abilities to promote 
OCL formation (Figure 4, C and D) and bone-resorptive activity 
(Figure 4, E and F), confirming that MMP-13 proteolytic activity 
is not required for the induction of osteoclastogenesis. Following 
knockin of MMP-13 WT or MMP-13 E223A into 5TGM1 MMP-13–
KD cells (Supplemental Figure 8A), OCL induction was rescued 
in Transwell coculture assays (Supplemental Figure 8, B and C). 
While recent studies have suggested that proteinase-independent 
activities of selected MMPs may reside within the C-terminal 
hemopexin domain (26–30), neither the recombinant MMP-13 
hemopexin nor the recombinant procatalytic domain alone (Sup-
plemental Figure 9A) were able to reconstitute the activity of the 
full-length enzyme (Supplemental Figure 9, B and C).
DC-STAMP, a master fusogen essential for normal OCL 
function, is induced by RANKL via NFATc1 (31, 32). Consistent 
with the MMP-13–dependent inductive activity of OCL fusion, 
both the WT and E223A mutant forms of the proteinase upreg-
ulated NFATc1 and DC-STAMP expression at both the protein 
and mRNA levels in developing OCLs (Figure 4G and Supple-
mental Figure 10, A and B). Flow cytometric staining confirmed 
the induction of cell-surface DC-STAMP expression by MMP-13 
MMP-13 mediates MM-induced OCL fusion and bone resorption. 
To assess the potential impact of MM-derived MMP-13 on OCL 
function, mouse BM mononuclear cells (the source of OCL progen-
itors) were cultured in the lower compartment of Transwell dishes 
with murine 5TGM1 MM cells seeded in the upper compartment in 
the absence or presence of IL-6. Either IL-6 or 5TGM1 cells alone 
stimulated OCL formation (Supplemental Figure 2, A and B). How-
ever, in the presence of both IL-6 and 5TGM1 cells, OCL formation 
was significantly enhanced, both in terms of increased average size 
and nuclei numbers (Supplemental Figure 2, A and B), indicating 
that IL-6–stimulated MM cells secreted soluble factors that are 
capable of promoting OCL fusion and activity (2). To determine 
the degree to which MMP-13 participates in pro-osteoclastogenic 
activity, the metalloproteinase was silenced in mouse 5TGM1 MM 
cells by lentiviral shRNA transduction (confirmed by quantitative 
reverse transcription PCR [qRT-PCR]; Supplemental Figure 3). 
While coculture with 5TGM1 empty vector–transduced (EV-trans-
duced) cells significantly increased OCL fusion relative to medium 
alone, 5TGM1–MMP-13–knockdown #1 (5TGM1–MMP-13–KD #1) 
cells largely lost the ability to induce OCL fusion, as reflected in the 
decreased OCL size and nuclei numbers. Underlining the specific-
ity of the silencing strategy, OCL fusion was rescued by exogenous 
pro–MMP-13 (Figure 2, A and B).
A required role for MMP-13 in controlling 5TGM1-induced 
osteoclastogenesis raised the possibility that the proteinase either 
modulates MM function or acts as an osteoclastogenic factor. In 
OCL formation assays, pro–MMP-13 directly enhanced mouse 
(Figure 2, C and D) as well as human OCL formation in a concen-
tration-dependent manner (Figure 2, E and F). As observed in the 
intact MM cell model, pro–MMP-13 increased both OCL size and 
nuclei numbers (Figure 2, D and F) without affecting pre-OCL 
proliferation (Supplemental Figure 4A). As a result of increased 
fusion, we observed a trend toward decreased OCL numbers (Fig-
ure 2D and Supplemental Figure 2B). Time course assays adding 
MMP-13 on days 1 and 2 only, on days 3 and 4 only, or on days 1–4 
of OCL culture revealed that the presence of MMP-13 is critical 
during the entire culture period in order to induce OCL fusion 
(Supplemental Figure 4B), without significant effects on cell pro-
liferation (Supplemental Figure 4C). Consistent with the increase 
in OCL size and nuclei numbers, the bone-resorptive activity of 
OCLs also increased as a function of MMP-13 concentration (Sup-
plemental Figure 4, D and E). By contrast, supplementing cultures 
with either MMP-1, MMP-2, or MMP-9, three other MMPs whose 
expression has been linked previously to tumor-related bone 
metastasis (22), exerted no significant effects on OCL develop-
ment (Supplemental Figure 5, A and B).
The ability of exogenous MMP-13 to support osteoclasto-
genesis as well as OCL activity raised the possibility that OCL 
progenitors may express MMP-13 as an endogenously derived 
pro- osteoclastogenic agent. Indeed, WT, but not Mmp13–/–, 
BM-derived mononuclear cells expressed Mmp13 as assessed by 
qRT-PCR (Supplemental Figure 6A). Furthermore, OCL forma-
tion from Mmp13–/– BM–derived mononuclear cells was signifi-
cantly impaired relative to that observed in WT cells, as evidenced 
by significant decreases in OCL size, nuclei numbers (Supplemen-
tal Figure 6, B and C), and bone-resorptive activity (Supplemental 
Figure 6, D and E). As predicted, defects in Mmp13–/– OCL forma-
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(refs. 38, 39, and Supplemental Figure 12C), indicating that MMP-
13 upregulates ERK signaling via an enzymatic activity–indepen-
dent mechanism. More important, following the inhibition of ERK 
signaling with U0126 (40), the ability of either MMP-13 WT or the 
E223A mutant to induce NFATc1 and DC-STAMP upregulation 
and OCL fusion was blocked (Figure 4, G and H). Taken together, 
these data indicate that pro–MMP-13 functions as a secreted acti-
vator of an ERK signal transduction cascade that induces both 
NFATc1 and DC-STAMP expression.
MMP-13 drives MM-induced osteolysis in vivo. To assess the role 
of MMP-13 in the development of MM-associated bone disease in 
vivo, we next used an intratibial 5TGM1 murine model that reca-
pitulates myeloma tumor growth coupled with severe osteolysis 
(41). To this end, GFP-expressing 5TGM1 cells were lentivirally 
transduced with EV control or 2 distinct shRNA expression vectors 
(Supplemental Figure 10C and refs. 33, 34). Consistent with these 
findings, Mmp13–/– OCLs also generated lower expression levels 
of NFATc1 and DC-STAMP, both of which were partially rescued 
by exogenous MMP-13 (Supplemental Figure 11). Interestingly, 
MMP-13 has recently been reported to activate ERK1/2 signaling 
in chondrocytes (35). As ERK1/2 can serve as a potential regula-
tor of the NFATc1/DC-STAMP axis (36), we sought to determine 
whether MMP-13 drives osteoclastogenesis through this signal 
transduction cascade. Indeed, both MMP-13 WT and the E223A 
mutant directly activated ERK signaling in BM-derived pre-OCLs 
(Supplemental Figure 12A). Further mechanistic studies indi-
cated that both MMP-13 WT and the E223A mutant upregulated 
TRAF6 polyubiquitination (ref. 37 and Supplemental Figure 12B) 
and induced phosphorylation of the ERK upstream kinases c-Raf 
and MEK1/2, as well as the downstream target substrate p90RSK 
Figure 3. MMP-13–dependent osteoclastogenesis proceeds independently of pro–MMP-13 activation. (A) Mouse nonadherent BM cells were cultured for 
4 days with M-CSF (10 ng/ml) and RANKL (50 ng/ml) to induce OCL differentiation in the absence or presence of pro–MMP-13 (200 ng/ml). Top panel: cul-
ture media were collected at the indicated times after the addition of pro–MMP-13. Processing of pro–MMP-13 to mature/active MMP-13 was assessed by 
Western blotting. Pro– and active recombinant MMP-13 protein standards were loaded as controls. Lower panel: OCL lysates isolated from cells incubated 
with or without pro–MMP-13 were analyzed by Western blotting. Data are representative of 4 independent experiments. WCL, whole-cell lysate. (B) Mouse 
nonadherent BM cells were cultured as described in A, in the absence or presence of pro–MMP-13 and the MMP-13 synthetic inhibitor CP544439 or CAS 
544678-85-5, at the indicated concentrations. OCL formation was assessed by TRAP staining. Scale bars: 100 μm. Data are representative of 3 indepen-
dent experiments. (C) OCL size, number of nuclei per OCL, and number of OCLs per field in B were determined by microscopy and ImageJ analysis. Data 
represent the mean ± SEM (n = 3). *P ≤ 0.05, by ANOVA.
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directed against MMP-13 (MMP-13–KD #1 and MMP-13–KD #2), 
thereby acting to efficiently silence metalloproteinase expression 
(confirmed by qRT-PCR and collagen zymography; Supplemental 
Figure 13, A and B), without affecting 5TGM1 cell proliferation 
(Supplemental Figure 13C). 5TGM1-GFP-EV, 5TGM1-GFP–MMP-
13–KD #1, or 5TGM1-GFP–MMP-13–KD #2 cells were injected 
intratibially into Rag2–/– mice (41), and after a 4-week incubation 
period, tibiae were harvested for histological analysis, followed 
by micro-quantitative CT (micro-qCT). As shown in Figure 5, 
intratibial injection of 5TGM1-GFP-EV cells disrupted normal 
Figure 4. MMP-13 proteolytic activity is not required for OCL induction. (A) SDS-PAGE analysis of purified WT pro–MMP-13 and E223A pro–MMP-13.  
M, molecular weight marker. (B) Proteolytic activity of purified MMP-13 WT and E223A proteins was analyzed by fluorometric assay and compared with 
standard MMP-13 (mean ± SD; n = 3). Data are representative of 3 independent experiments. (C) For OCL induction, mouse nonadherent BM cells were 
cultured with WT pro–MMP-13 or the pro–MMP-13 E223A mutant in the presence of M-CSF (10 ng/ml) and RANKL (50 ng/ml) for 4 days. OCLs were 
stained for TRAP. Scale bar: 100 μm. Data are representative of 5 independent experiments. (D) OCL size, number of nuclei per OCL, and number of OCLs 
per field in C were determined as described above. Data represent the mean ± SEM (n = 3). **P ≤ 0.01, by ANOVA (left panel) and *P ≤ 0.05, by Poisson 
ANOVA (middle panel). (E and F) Mouse nonadherent BM cells were seeded atop dentin slices and cultured as described in C for 9 days. Bone resorption 
lacunae were visualized by hematoxylin staining. Bone resorption area was calculated by ImageJ software. Data represent the mean ± SEM (n = 3) and 
are representative of 3 independent experiments. **P ≤ 0.01, by ANOVA (E). Scale bars: 100 μm (F).(G and H) Mouse nonadherent BM cells were cultured 
as described in C, with or without pro–MMP-13 WT or the pro–MMP-13 E223A mutant, in the presence of U0126 (5 μM) or vehicle control for 4 days. (G) 
DC-STAMP, NFATc1, p-ERK1/2, and ERK2 expression levels were determined in OCL lysates by Western blot analysis. Band intensities were quantified by 
ImageJ software, normalized to β-actin, and compared with control. Relative intensities are shown. (H) OCL differentiation analyzed by TRAP staining. 
Data are representative of 2 independent experiments. Scale bars: 100 μm.
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hematopoiesis in association with the development of extensive 
lytic lesions, resulting in the destruction of trabecular bone. MMP-
13–KD #1 and –KD #2 MM cells also infiltrated the BM, but with-
out completely replacing hematopoietic centers. Most important, 
in contrast to control 5TGM1-GFP-EV cells, bone structure was 
maintained with markedly less bone loss when recipient mice were 
inoculated with MMP-13–KD #1 or –KD #2 MM cells (Figure 5, top 
panel). As expected, while enlarged TRAP+ OCLs were observed 
adjacent to the 5TGM1-GFP-EV tumor, only small TRAP+ OCLs 
were detected in mice injected with 5TGM1-GFP–MMP-13–KD #1 
or –KD #2 cells (Figure 5, bottom panel). Quantification of OCL 
numbers and size confirmed that MMP-13–KD decreased OCL 
size as determined by the OCL surface to bone surface ratio (Sup-
plemental Figure 14).
Bone micro-qCT and morphological analysis of the tibiae and 
adjacent femurs demonstrated that 5TGM1-GFP-EV myeloma 
cells not only induced lytic bone lesions, but also resulted in tra-
becular bone loss (Figure 6A). By contrast, MMP-13–KD #1 or –KD 
#2 MM cells significantly inhibited the formation of MM-induced 
bone lesions (Figure 6A). These effects were further supported by 
our morphological analyses of trabecular bones (Figure 6B), in 
which MMP-13–KD #1 or –KD #2 MM cells significantly increased 
the bone volume fraction (bone volume/total volume [BV/TV]: EV 
0.0573 vs. KD #1, 0.0723 and KD #2, 0.0987), connective density 
(Con.D.: EV 50.53 vs. KD #1, 83.69 and KD #2, 142.0 mm3), trabe-
cular numbers (Tb.N.: EV 3.081 vs. KD #1, 3.440 and KD #2, 3.368 
mm–1), and bone mineral density (BMD: EV 125.3 vs. KD #1, 150.9 
and KD #2, 181.9 mg/cm3), while decreasing the bone surface to 
bone volume ratio (BS/BV: EV 74.44 vs. KD #1, 71.53 and KD #2, 
64.01 mm–1) and the structure model index (SMI: EV 3.257 vs. KD 
#1, 3.023 and KD #2, 2.610). Hence, silencing of MM-derived 
MMP-13 inhibits osteolysis in vivo, further confirming its critical 
role in MM bone disease.
In a second set of animal experiments, we focused on the 
effects of MMP-13 silencing on MM tumor progression. Four 
weeks after intratibial injection of 5TGM1-GFP-EV or 5TGM1-
GFP MMP-13–KD #1 cells, serum levels of mouse IgG2b were 
measured to assess tumor burden, while tibiae were harvested for 
histological analysis as well as GFP imaging, followed by micro-
qCT. Similarly, the BM infiltration of MMP-13–KD #1 MM cells 
caused markedly less bone loss compared with that seen with 
5TGM1-GFP-EV cells (Supplemental Figure 15A, top panel) and 
the formation of smaller OCLs in juxtaposition to MM cells (Sup-
plemental Figure 15A, bottom panel). Despite the fact that MMP-
13 had no direct effect on MM cell growth, as demonstrated by 
in vitro 3H-thymidine incorporation assay (Supplemental Figure 
15B), the decreased OCL activity and subsequent bone disease led 
to a slightly lower MM tumor burden in vivo, as reflected by quan-
titative fluorescence imaging (Supplemental Figure 15, C and D) 
and IgG2b secretion (Supplemental Figure 15E). Consistent with 
the previous results, micro-qCT analysis again showed that MMP-
13 silencing blocked the formation of MM-induced bone lesions 
in both the tibiae and adjacent femurs (Supplemental Figure 16).
MMP-13 expression in patients’ plasma cells and serum. Given 
the key role played by MMP-13 in regulating MM-induced osteo-
clastogenesis in our model systems, we next sought to determine 
whether MMP-13 expression levels might serve as an index of 
bone disease in patients. MMP-13 expression was first monitored 
in marrow biopsies of a cohort of patients with MM and controls. 
In tissue arrays of 11 normal biopsy samples and 10 MM samples, 
MMP-13 expression was specifically and highly expressed in pri-
mary MM BM samples (Figure 7A, bottom panel; 9 of 10 sam-
ples), but not in any of the normal control samples (Figure 7A, top 
panel; 0 of 11 samples). Given that MMP-13 is a secreted protein, 
we considered the possibility that serum levels of the metallopro-
teinase could reflect the presence of active bone disease. As such, 
we determined MMP-13 serum levels in 32 patients with MM and 
in 6 healthy donors. As shown in Figure 7B, 10 of 18 patients with 
MM-associated bone disease showed positive serum expression 
levels of MMP-13, while none of the 14 MM patients without 
bone disease had detectable levels of MMP-13. Further, MMP-13 
was not detected in any of the 6 healthy donors. Thus, consistent 
Figure 5. MMP-13 directs 
MM-induced OCL in vivo. PBS, 
5TGM1-GFP-EV MM cells, 5TGM1-
GFP–MMP-13–KD #1 MM cells, or 
5TGM1-GFP–MMP-13–KD #2 MM cells 
were injected bilaterally into both 
tibiae (n = 24) of Rag2–/– mice. Mice 
were sacrificed 4 weeks later and the 
tibiae formalin-fixed, followed by 
paraffin sectioning. Sections were 
then subjected to H&E and TRAP 
staining. Representative images are 
shown for each set of conditions. 
Scale bars: 100 μm.
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ated OCLs. Unexpectedly, in contrast to previous studies that 
have sought to identify potential roles for MMPs in bone-resorp-
tive disease states, MMP-13 exerts its pro-osteoclastogenic effects 
independently of a requirement for proteolytic activity by acting 
as a DC-STAMP–inducing secretagogue. Complementing these in 
vitro studies, the pathophysiological relevance of our findings are 
highlighted by the demonstration that silencing MMP-13 expres-
sion in MM cells exerts bone-sparing effects in a mouse MM dis-
ease model. In extending these findings to human populations, 
MMP-13 was readily detected at both the MM-BM interface and in 
the serum of a subset of patients with active bone disease.
with a pivotal role for MMP-13 in MM-associated bone disease, 
serum MMP-13 levels were specific for bone disease status in a 
significant subset of affected patients.
Discussion
Following their homing to the BM compartment, MM cells secrete 
OCL activation factors that contribute to the formation of bony 
lesions in affected patients (1–6, 42). Here, we demonstrate that 
IL-6–mediated MM-BMSC interactions induce MMP-13 expres-
sion that, in turn, serves as a potent osteoclastogenic factor capa-
ble of promoting the generation of bone-resorptive, multinucle-
Figure 6. MMP-13 directs MM-induced osteolysis. (A) Tibiae from Figure 5 were analyzed by 3D micro-qCT scanning. Representative 3D images of tibiae, 
adjacent femurs (top panel), and tibiae trabecular bones (bottom panel) from each treatment regimen are shown. Scale bars: 1 mm (top panel); 100 μm 
(bottom panel). (B and C) Trabecular bone of mice tibiae were analyzed, and microstructural parameters, including bone volume fraction (BV/TV), Con.D., 
Tb.N., BMD, BS/BV ratio, and SMI, were determined. Results are presented as the mean ± SEM (n = 24). *P ≤ 0.05 and **P ≤ 0.01, by ANOVA.
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52–55). Interestingly, MT1-MMP has been recently reported to 
support normal OCL function via a Rac1-dependent process 
that proceeds independently of the proteolytic activity of the 
enzyme (55). These latter observations, taken together with 
those presented here for MMP-13, suggest that OCL function 
may be modulated by a subset of catalytically inactive MMPs 
expressed in both a cell-autonomous and non–cell-autono-
mous fashion. Indeed, consistent with the pro-osteoclastogenic 
effects of exogenous MMP-13 found in vitro, Mmp13–/– OCLs 
also showed defects in form and function in vitro. Underlining 
these effects, Mmp13–/– mice have previously been reported to 
show an osteopetrotic phenotype with increased trabecular 
bone volume and bone mineral density (16, 56, 57), along with 
increased callus bone volume and bone mineral density during 
active bone remodeling following fracture (10). Given these 
findings, we considered the possibility that MMP-13 might also 
affect osteoblast (OB) formation or MM cell behavior itself, as 
both cell types express the metalloproteinase (Supplemental 
Figure 17A). However, MMP-13 supplementation did not affect 
OB differentiation, MM proliferation, or MM responses to the 
antineoplastics bortezomib or pomalidomide (Supplemental 
Figure 17B and Supplemental Figure 18, respectively). Similarly, 
MMP-13 silencing in MM cells showed no inhibitory effects on in 
vitro MM growth or MM-induced OB inhibition in vivo (Supple-
mental Figure 13C and Supplemental Figure 17C, respectively).
MM cells have long been known to express multiple MMPs 
that extend beyond MMP-13, including MMP-1, MMP-2, MMP-
7, MMP-8, MMP-9, and MT1-MMP (43–46). The biologic ratio-
nale for the expression of multiple MMPs by MM cells remains 
unclear, but studies performed to date have most frequently 
stressed their role in supporting the tissue-trafficking activity 
of the neoplastic clones as they encounter basement membrane 
and interstitial matrix barriers in vivo (44, 45). While no specific 
functions have been assigned previously to MM-derived MMP-
13, recent studies have proposed roles for the metalloproteinase 
in promoting tumor-associated osteolytic lesions in breast can-
cer as well as giant-cell tumors (15, 47–50). In each of these cases, 
however, the preferred mode of MMP-13–dependent activity 
is the proteolysis of downstream targets thought to play direct 
or indirect roles in bone resorption, including type I collagen, 
RANKL, osteoprotegerin, galectin 3, and TGF-β (15, 47–51). By 
contrast, all of the pro-osteoclastogenic effects associated with 
the WT proteinase in our studies could be recapitulated by a cat-
alytically inactive E223A MMP-13 mutant. At first glance, the 
proposition that a catalytically inactive MMP mediates unique 
biological activities seems counterintuitive. More recently, how-
ever, a small subset of MMP family members, including catalyt-
ically inactive forms of MMP-3, MMP-9, and MT1-MMP, have 
been shown to affect a range of cell responses, ranging from 
cell motility to energy metabolism and cytokine expression (26, 
Figure 7. BM and serum MMP-13 levels in MM 
patients. (A) Tissue arrays of normal costal 
tissue (top panel, n = 10) and of tissue from MM 
patients (bottom panel, n = 11) were subjected to 
immunohistochemical staining using an hMMP-
13 Ab. Scale bars: 20 μm. (B) MMP-13 levels in 
sera from healthy donors (n = 6) and from MM 
patients with bone disease (MMBD) (n = 18) 
and without MMBD (n = 14) were determined by 
ELISA. *P ≤ 0.05 and **P ≤ 0.01, by 2 Wilcoxon 
rank-sum tests with Bonferroni’s correction.  
(C) Role of MMP-13 in MM: IL-6 expressed in 
the BM microenvironment induces MMP-13 
secretion from MM cells. MMP-13 subsequently 
activates ERK1/2 signaling in OCL precursors 
and mediates the subsequent induction of 
NFATc1 and DC-STAMP expression, resulting in 
enhanced OCL fusion, activity, and osteolysis.
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events operative at the OCL-bone interface, we were surprised 
to find that nearly 60% of the 18 patients with MM identified 
with active bone disease who were monitored in our study reg-
istered detectable blood levels of MMP-13. At this juncture, we 
cannot rule out the possibility that the cohort of patients with 
bony lesions and undetectable serum MMP-13 levels are no lon-
ger actively remodeling bone. As such, further studies are under-
way to monitor serum MMP-13 levels in tandem with markers of 
active bone turnover. In any case, our findings suggest that, in 
contrast to interventions designed to target pro–MMP-13–OCL 
interactions, MMP-13 catalytic activity inhibitors would be pre-
dicted to exert little, if any, effect on MM-associated bone dis-
ease. As such, efforts designed to identify the MMP-13 receptor 
as well as the critical MMP-13 domains responsible for receptor 
binding and signaling may well lead to the development of a new 
class of bone-sparing therapeutics for the treatment of MM and 
related bone lytic disease states.
Methods
Animals. C57BL/6 WT mice were purchased from The Jackson Labora-
tory. C57BL/6 Mmp13–/– mice were maintained as previously described 
(57). For the 5TGM1 intratibial MM bone disease model, 8- to 10-week-
old C57BL/6 Rag2–/– female mice were purchased from Taconic.
Patients’ samples and analysis. BM aspirates were obtained from 
patients with MM, while serum samples were obtained from either 
healthy controls or MM patients with or without clinically confirmed 
(by x-ray or CT) bone disease. MMP-13 levels were determined using a 
human MMP-13 ELISA kit (EMD Millipore).
For BM and tissue samples, tissue microarray slides (US Biomax) 
were prepared from formalin-fixed, paraffin-embedded normal and 
MM tissues. One slide included 21 well-characterized, randomly 
selected samples from 10 MM patients and 11 normal costal tissues. 
Five-micrometer sections of 1.5-mm-diameter cores were stained 
using a human MMP-13 (hMMP-13) Ab (clone VIIIA2; Calbiochem), 
combined with Dako EnVision Systems HRP (DAB).
Cells. The human MM cell lines RPMI-8226, H929, and U266 
were purchased from the ATCC. MM.1R and OPM2 were provided by 
Klaus Podar (Dana-Farber Cancer Institute, Boston, Massachusetts, 
USA). All cell lines were cultured as previously described (64, 65). 
The murine MM cell line 5TGM1-GFP was cultured in IMDM medium 
with L-glutamine, penicillin-streptomycin, and 10% FBS. The mouse 
monocyte/macrophage cell line RAW264.7 and the pre-OB cell line 
MC3T3-E1 subclone 4 were purchased from the ATCC and cultured 
in α-MEM or α-MEM without ascorbic acid (Life Technologies) sup-
plemented with L-glutamine, penicillin-streptomycin, and 10% FBS, 
respectively. Mouse primary BMSCs were collected by culturing 
adherent mouse BM cells in Iscove’s modified Dulbecco’s medium 
(IMDM) medium with L-glutamine, penicillin-streptomycin, and 10% 
FBS until confluence was reached. Human peripheral blood mononu-
clear cells (PBMCs) were separated by Ficoll gradient separation, then 
enriched by Monocyte Enrichment Cocktail (STEMCELL Technolo-
gies) according to the manufacturer’s instructions (34).
Luminex screening assay. Cell culture supernatants were screened 
for secreted MMPs (MMP-1,-2,-3,-7,-8, -12, and -13) or cytokines using 
Luminex assays (Luminex Core Facility at the University of Pitts-
burgh). The bead set conjugated with a capture Ab specific to a unique 
target protein was mixed with a 50-μl cell culture supernatant sample. 
In light of the finding that MMP-13 induces OCL activation 
independently of its enzymatic activity, we assessed the effects 
of MMP-13 inhibition on MM bone lytic lesion and tumor pro-
gression by silencing MMP-13 expression, as opposed to using 
inhibitors directed against its enzymatic activity. Confirming our 
in vitro studies, MMP-13–KD significantly inhibited the develop-
ment of bone lytic lesions in vivo. Although MMP-13–KD did not 
affect MM cell growth during in vitro culture, we observed a mod-
est inhibition of MM tumor growth in the in vivo setting. This is in 
accordance with data showing that activated OCL cells contribute 
to adjacent MM growth (20). As such, the inhibition of MM growth 
in vivo most likely occurs as a consequence of effects secondary 
to decreased OCL activation within the bone microenvironment 
following MMP-13 silencing.
In considering the potential mechanisms by which MMP-
13 regulates osteoclastogenesis in normal as well as neoplastic 
states, our attention centered on DC-STAMP, a critical fusogenic 
factor whose deletion undermines OCL formation and function 
(32, 58). Indeed, MMP-13 directly activated both NFATc1 and 
DC-STAMP expression in developing OCLs. Furthermore, the 
ability of MMP-13 to promote OCL fusogenesis dovetailed the 
defects we observed in the maturation of Mmp13–/– myeloid pro-
genitors into multinucleated OCLs that likewise correlated with 
lower levels of NFATc1 and DC-STAMP expression. With regard 
to uncovering the MMP-13–dependent signaling cascades that 
underline OCL progenitor maturation, MMP-13 has been reported 
to activate ERK1/2 in chondrocytes as well as endothelial cells (35, 
59). In our studies, catalytically inactive MMP-13 similarly triggers 
an ERK1/2-dependent signal transduction cascade that in turn 
controls NFATc1 and DC-STAMP expression. As surface-bound 
MMP-13 can be recognized and internalized by the low-density 
lipoprotein receptor–related protein 1 (i.e., LRP1) (60), we con-
sidered the possibility that MMP-13–LRP1–binding interactions 
induced ERK1/2 phosphorylation. However, both MMP-13–
dependent ERK1/2 signaling and OCL formation were unaffected 
when LRP1 function was blocked with the receptor-associated 
protein (RAP) (data not shown) (35). Efforts are currently under-
way to identify the MMP-13 receptor(s) that are operative in OCL 
progenitors, with preliminary cross-linking and mass spectro-
scopic studies having identified a number of potential cell-surface 
ligands whose expression will require silencing on a one-by-one 
basis (our unpublished observation). These studies will, by neces-
sity, need to proceed cautiously, as several MMPs including MMP-
13 can regulate diverse cell functions by trafficking to the nuclear 
compartment to exert transcriptional effects (61, 62).
To date, all efforts to link MMPs to cancer-induced osteo-
lytic states including MM have emphasized the importance of 
proteolytic activity and the identification of targeted substrates. 
Not surprisingly, these studies have also accelerated efforts 
to identify new therapeutics that can specifically inhibit a sin-
gle, selected MMP target (63). Our findings, however, support 
an alternate, and previously unsuspected, role for the MMP-13 
zymogen as a MM-derived pro-osteoclastogenic secretagogue. 
Consonant with our in vitro and mouse model studies, MMP-13 
could be detected in the BM compartment of almost all patients 
with MM in the small cohort of 10 patients studied. While serum 
MMP-13 levels would not necessarily be predicted to reflect 
Downloaded from http://www.jci.org on August 22, 2017.   https://doi.org/10.1172/JCI80276
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
1 7 6 9jci.org   Volume 126   Number 5   May 2016
(both from R&D Systems) in the absence or presence of rh–pro–MMP-
13. Half-media changes were carried out every 3 days and OCL for-
mation assessed by staining with mAb 23c6 (CD51/61), which was 
provided by Michael Horton (Rayne Institute, Bone and Mineral 
Center, London, United Kingdom) using a VECTASTAIN ABC-AP Kit 
(Vector Laboratories) (66). For bone resorption pit assays, 2 × 105 BM 
mononuclear cells were seeded on dentin slices in 96-well plates and 
treated as described above for 21 days. The number of OCLs per well, 
the number of nuclei per OCL, and OCL size were quantified using 
an Olympus IX70 microscope equipped with a 20/0.40 numeric aper-
ture objective lens and SPOT software (Diagnostic Instruments) or a 
Leica DMI 6000B fluorescence microscope equipped with an HCX 
PL S-APO 10×/NA 0.3 objective lens, coupled with a Leica DFC365 
FX digital camera and operated by LAS AF 6.2 software (Leica Micro-
systems). Images of resorption lacunae were captured using an OMAX 
40X-2000X Digital Microscope with ScopeImage 9.0 software 
(BioImager) or Magnafire 4.1 software (Optronics).
OB differentiation. MC3T3 E1 cells (1 × 104) were seeded in 24-well 
culture dishes in OB differentiation media (α-MEM without ascorbic 
acid, supplemented with 10% FBS, 1% penicillin-streptomycin, 50 μg/
ml L-ascorbic acid, and 2 mM β-glycerophosphate), with or without 
MMP-13 (200 ng/ml), for up to 14 days. Media were changed every 3 
days, and, at the times indicated in Supplemental Figure 17B, cultures 
were fixed in 4% paraformaldehyde for 10 minutes and stained for 
alkaline phosphatase or alizarin red.
Immunoblot analysis. Immunoblotting was performed as described 
previously (64, 67) using the following Abs: anti–MMP-13 (ab39012; 
Abcam); anti–DC-STAMP (clone 1A2; EMD Millipore); anti-NFATc1 
(7A6) and anti-TRAF6 (H274) (both from Santa Cruz Biotechnology 
Inc.); anti-ubiquination (Ubi-1; Thermo Fisher Scientific); anti–phos-
phorylated–c-Raf (anti–p–c-Raf) (Ser338) (56A6), anti–p-MEK1/2 
(Ser217/221), anti–p-ERK1/2 (D13.14.4E), anti–p-p90RSK (Ser380) 
(D3H11), and anti-ERK2 (9108) (all from Cell Signaling Technology); 
and β-actin (Sigma-Aldrich).
qRT-PCR analysis. Total RNA was isolated with TRIzol reagent 
(Thermo Fisher Scientific) and cDNA generated with SuperScript III 
reverse transcriptase (Invitrogen), followed by SYBR Green–based 
(Invitrogen) qRT-PCR assays performed as previously described 
(64). Primer pairs were as follows: human MMP13: forward, 5′-GAT-
GGGCCCTCTGGCCTGCT; reverse, 5′-TGGCCGAACTCATG-
CGCAGC; human β-actin: forward, 5′-CGAGCACAGAGCCTC-
GCCTTTG; reverse, 5′-CGACGAGCGCGGCGATATCAT; mouse 
Mmp13: forward, 5′-GGTCCAGGCGATGAAGACCCC; reverse, 
5′-GGGTGCAGGCGCCAGAAGAA; and mouse β-actin: for-
ward, 5′-AACCCTAAGGCCAACCGTGAAA; reverse, 5′-CGAC-
CAGAGGCATACAGGGACAG. Mouse Nfatc1 and Dcstamp mRNA 
were analyzed by TaqMan qRT-PCR (Life Technologies).
Flow cytometric assay. For flow cytometric analysis, human 
PBMCs or mouse OCLs were harvested, washed once with FACS buf-
fer (HBSS buffer supplemented with 0.5% BSA and 0.1% NaN3), and 
incubated with primary Ab mouse anti–DC-STAMP clone 1A2 (EMD 
Millipore) and Fc receptor blocker anti-CD16/CD32 (BD Pharmin-
gen) at room temperature for 20 minutes. Cells were rewashed with 
FACS buffer and finally incubated with FITC-conjugated goat anti-
mouse secondary Ab (Invitrogen) at room temperature for 20 min-
utes. FACS data were acquired using a BD FACSCanto System and 
analyzed by FlowJo software (34, 67).
After washing, secondary biotin-conjugated Ab was added to form a 
capture sandwich immunoassay. Streptavidin-R-phycoerythrin solu-
tion was added and incubated for 30 minutes. A Luminex array reader 
was used to determine MMP and cytokine concentrations on the basis 
of 7-point standard curves.
Coculture experiments. Primary BMSCs from patients with MM 
were seeded in 96-well plates at 4 × 103 cells per well in RPMI 1640 
supplemented with 10% FCS. After 24 hours, human MM cells (4 × 104 
cells/well) were seeded on the BMSC layer and cocultured for an 
additional 48 hours. MMP-13 concentrations in recovered superna-
tants were determined using a human MMP-13 Fluorokine E Kit (R&D 
Systems). To confirm the cell source of MMP-13 in cocultures, human 
BMSCs were precultured at a concentration of 3 × 104 cells per well in 
24-well plates for 24 hours. GFP+ RPMI 8226 cells (1 × 105 cells/well) 
were then seeded onto the stromal cell monolayer for 48 hours. MMP-
13 expression in RPMI 8226 cells and BMSCs was measured by qRT-
PCR following the separation of GFP– BMSCs from GFP+ RPMI 8266 
cells by flow cytometry. β-actin was used as a loading control.
Transwell assays. BMSCs (3 × 104 cells/well) were cultured for 24 
hours in the lower chambers of 24-well Transwell plates. MM cells 
(1 × 105 cells/well) were seeded in the upper chamber and cocultured 
for an additional 48 hours. MMP13 mRNA expression in MM cells was 
measured by qRT-PCR. For MM-OCL Transwell coculture assays, 
mouse nonadherent BM cells (1.5 × 106 cells/well) were cultured in 
the lower chambers of 24-well Transwell plates with murine macro-
phage-CSF (mM-CSF) (10 ng/ml) and mRANKL (50 ng/ml) (both from 
R&D Systems). 5TGM1 EV or 5TGM1-MMP-13–KD cells (3 × 105 cells/
well) were seeded in the upper chamber and cocultured for 4 days.
BMSC CM. BMSCs (5 × 105) isolated from patients with MM were 
cultured in 100-mm dishes for 24 hours in 10% FCS-DMEM media. 
The cells were then washed with PBS and cultured with fresh 5% 
FCS-DMEM media for a 3-day incubation period. The CM was col-
lected by centrifugation (500 g for 15 minutes) and cell-free aliquots 
stored at –80°C until use.
OCL formation and bone resorption assays. For mouse cell studies, 
1.5 × 105 nonadherent BM mononuclear cells from C57BL/6 mice (4–6 
weeks of age) were cultured in 96-well plates in α-MEM supplemented 
with 10% FBS, 10 ng/ml mM-CSF, and 50 ng/ml mRANKL (R&D 
Systems) in the presence or absence of recombinant human (rh) pro–
MMP-1, -2, -9 or -13 (R&D Systems) for 4 days. Half-media change was 
carried out on day 3. The cells were then fixed in formalin and stained 
for TRAP using a TRAP staining kit (Sigma-Aldrich). TRAP+ cells con-
taining 3 or more nuclei were counted as OCLs. For bone resorption 
pit assays, 2 × 105 BM mononuclear cells were seeded on dentin slices 
in 96-well plates and treated as described above for 9 days. OCL for-
mation on dentin slices was confirmed by TRAP staining and bone 
resorption lacunae identified following hematoxylin staining (66). To 
investigate MMP-13–induced ERK1/2 signaling in pre-OCLs, CD11b+ 
cells were purified by CD11b microbeads (Miltenyi Biotec) and cul-
tured for 3 days with 10 ng/ml M-CSF and 50 ng/ml RANKL. After 
4 hours of serum-free starvation, MMP-13 WT or the E223A mutant 
(200 ng/ml) was added for the durations indicated in Supplemental 
Figure 12A prior to collection of lysates for Western blot analysis.
For human cell studies, BM mononuclear cells (1 × 105 cells/
well) isolated from patients with MM were seeded in 96-well plates 
in α-MEM supplemented with 20% horse serum, 10 ng/ml human 
M-CSF (hM-CSF), and 50 ng/ml soluble human RANKL (hRANKL) 
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tively. The proteolytic activity of WT and E223A mutant MMP-13 
was determined with an MMP-13 Fluorokine E Kit (R&D Systems) 
after pretreatment with 1 mM 4-aminophenylmercuric acetate) 
(Sigma-Aldrich) at 37°C for 1 hour, according to the manufacturer’s 
instructions, and its activity compared with commercially obtained 
MMP-13 protein (R&D Systems) as an internal standard. In all cell 
cultures, MMP-13 was used at a concentration of 200 ng/ml unless 
stated otherwise.
3H-thymidine incorporation assay. 5TGM1-GFP-EV or MMP-13–
KD cells (3 × 104 cells) were  incubated in 96-well plates in 200 μl 
IMDM containing 10% FBS at 37°C and 5% CO2 for 2 days. DNA 
synthesis was measured by 3H-thymidine incorporation (NEN Prod-
ucts, PerkinElmer Life and Analytical Sciences). Cells were pulsed 
with 3H-thymidine (1 μCi/well or 0.037 MBq) for the last 8 hours of 
culture, harvested onto glass fiber filter mats (Wallac) using an auto-
matic cell harvester (Harvester 96, Mach III; Tomtec), and counted 
using a Wallac TriLux Beta Plate Scintillation Counter (PerkinElmer 
Life and Analytical Sciences) (64).
Cell proliferation assay. MM cells (1 × 104) or CD11b+ mouse BM 
mononuclear cells (1 × 105) were incubated in 96-well plates in 100 μl 
culture medium with bortezomib (100 nM), pomalidomide (2 μM), or 
vehicle, with or without MMP-13 (200 ng/ml), at 37°C and 5% CO2 for 
up to 3 days. DMSO was added in the control group. Ten microliters 
of Premixed WST-1 Cell Proliferation Reagent (Clontech, Takara Bio) 
was added to each well for 4 hours and absorption determined in an 
ELISA reader (BioTek Instruments).
Collagen zymography. MM cells, RAW264.7 cells, MC3T3-E1 clone 
4, or mouse primary BMSCs were cultured in standard medium until 
confluent and then switched to Opti-MEM I serum-free medium 
(Thermo Fisher Scientific) for 3 days. Medium was collected and con-
centrated by Amicon ultracentrifugal filtration (EMD Millipore). The 
concentrated supernatants were analyzed by 10% SDS-PAGE gel con-
taining 0.5% collagen type I as previously described, and gels were 
stained with Coomassie Brilliant Blue R250 (Thermo Fisher Scien-
tific) and then de-stained (68). In selected experiments, 0.4 μg puri-
fied MMP-13 WT or E223A mutant protein was incubated in MMP-13 
reaction buffer, with or without 1 mM APMA, for 20 minutes at 37°C 
and analyzed by collagen zymography. The molecular weight of pro–
MMP-13 is 60 kD, while that of activated MMP-13 is 48 kD (69).
Mouse MM model. 5TGM1-GFP EV or MMP-13–KD cells (1 × 105 
cells) were bilaterally injected into both tibiae of C57BL/6 Rag2–/– 
female mice as described previously (41, 70). Mice were sacrificed 
4 weeks later, and tibiae were collected for GFP imaging and then 
fixed in 4% neutral-buffered formalin for micro-qCT analysis. Fol-
lowing micro-qCT scanning, the same tibiae were decalcified with 
10% EDTA and subjected to histologic analysis. Tumor burden was 
assessed by serum analysis of the myeloma-specific IgG2b.
Micro-qCT analysis. Mice tibiae were dissected 4 weeks after 
tumor injection and fixed in 10% neutral-buffered formalin buffer for 
2 days. Trabecular bone from the proximal tibia and cortical bone at 
the tibia midshaft were scanned using a micro-qCT system (VivaCT 
40; Scanco Medical). For trabecular microstructure, 100 slices, cor-
responding to a 1.05-mm region underneath the growth plate, were 
obtained with 10.5 μm spatial resolution. For the cortical bone, 50 
slices, corresponding to a 1.05-mm region starting in a region that was 
56% of the tibia length from its proximal end, were obtained with 21 
μm spatial resolution. A global threshold technique was applied to seg-
Expression constructs and site-directed mutagenesis. WT human 
MMP13 cDNA was generated by PCR using cDNA prepared from 
RPMI 8266 cells as a template with the following primers: forward, 
5 ′-GACTGGAAT TCACCATGCATCCAGGGGTCCTGGCT-3 ′ ; 
reverse, 5′-GACTCTCGAGGCACACCACAAAATGGAATTTGC-3′. 
PCR products were then cloned into pcDNA 6/myc-His B (Invitro-
gen) after EcoRI-XhoI (New England BioLabs) double digestion. 
For generation of the MMP-13 E223A mutant, site-directed muta-
genesis PCR was performed with the pcDNA6/myc-His B–MMP-13 
WT construct as a template using the following primers: forward, 
5′-CTTGTTGCTGCGCATGCATTCGGCCACTCCTTA-3′; reverse, 
5′-TAAGGAGTGGCCGAATGCATGCGCAGCAACAAG-3′. Similarly, 
MMP-13 procatalytic domain (aa 1–267) constructs were generated 
by PCR using pcDNA6/myc-His B–MMP-13 WT as a template with 
the following primers: forward, 5′-GACTGGAATTCACCATGCATC-
CAGGGGTCCTGGCT-3′; reverse, 5′-GACTCTCGAGACCATAGA-
GAGACTGGAT-3′, followed by cloning into pcDNA 6/myc-His A 
after EcoRI-XhoI double digestion. An MMP-13 hemopexin domain 
(deletion 37-267) construct was generated by mutagenesis PCR with a 
pcDNA6/myc-His B-MMP-13 WT construct as a template and the fol-
lowing primers: forward, 5′-TCTGAGGAAGACCTCCCGGGAGAT-
GAAGACCCCAAC-3′; reverse, 5′-GTTGGGGTCTTCATCTCCCGG-
GAGGTCTTCCTCAGA-3′. Constructs were verified by sequencing 
and MMP-13 mutant protein expression confirmed by Western blot-
ting following transfection in HEK-293 cells.
Lentivirus infection and MMP-13 knockdown and knockin. To silence 
MMP-13 expression in mouse MM cells, 5TGM1-GFP cells were trans-
duced with an EV lentiviral control or an MMP-13–targeting shRNA 
lentiviral construct 1 (5′-CCGGGCCTTACATTTGGCTTAATTTCTC-
GAGAAATTAAGCCAAATGTAAGGCTTTTTG-3′) or an MMP-13–tar-
geting shRNA lentiviral construct 2 (5′-CCGGGCACTACTTGAAAT-
CATACTACTCGAGTAGTATGATTTCAAGTAGTGCTTTTTG-3′) 
(provided by Robert W. Sobol, Hillman Cancer Center, Pittsburgh, 
Pennsylvania, USA). 5TGM1-GFP cells were incubated with lentiviral 
particles and polybrene (8 μg/ml for 16 hours) and then washed. A sec-
ond infection was repeated 24 hours later. Cells were selected by cul-
turing for 14 days in puromycin (8 μg/ml). MMP-13 protein and mRNA 
levels were determined in control and silenced cells by Western blot-
ting and qRT-PCR, respectively. To knock MMP-13 WT or the E223A 
mutant into 5TGM1-GFP MMP-13–KD cells, MMP-13 WT or the E223A 
mutant was inserted into a pLHCX retroviral vector (Clontech). Retro-
viruses were packed by Phoenix-AMPHO cells (ATCC), and 5TGM1-
GFP MMP-13–KD cells were transduced as described above. Cells were 
selected by culturing for 14 days in hygromycin B (100 μg/ml). MMP-13 
protein was determined by Western blot analysis.
Protein purification. pcDNA6/myc-His B–MMP-13 WT, MMP-
13 E223A, as well as MMP-13 procatalytic domain (aa 1–267) and 
hemopexin domain (deletion aa 37–267) constructs were trans-
fected into HEK-293 cells using Lipofectamine 2000 (Invitrogen) 
and cultured in Opti-MEM serum-free medium (Thermo Fisher 
Scientific). Cell culture media were collected 48 hours after trans-
fection, concentrated by ultrafiltration, and incubated with Ni-NTA 
agarose (QIAGEN) at 4°C for 2 hours. The tagged proteins were 
washed, eluted according to the manufacturer’s protocol, de-salted 
by ultrafiltration, and resuspended in PBS. Protein purity and con-
centration were determined by Coomassie Brilliant Blue R-250 
staining following SDS-PAGE and a Bradford protein assay, respec-
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from healthy controls and MM patients under an IRB-approved tissue 
repository protocol at the University of Pittsburgh Cancer Institute 
(UPCI 86-22) and Columbia University Medical Center (AAAL9054).
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